Table 1.

Patient characteristics

Risk Factor		Surgical Status		HR	95% CI		p-value
		Avoid (n =149)	Undergo (n =72)
Gender		62 (41.61%)	30 (41.67%)	1.02	0.639	1.632	0.929
Age		42.05 (14.65)	38.71 (17.52)	0.99	0.973	1.005	0.173
Perianal Fistula		17 (11.49%)	16 (22.22%)	1.88	0.839	3.286	0.124
Medication Use Prior to Hospitalization
Prednisone
	Omg	117 (78.5%)	52 (72.2%)		reference
	0-19mg	12 (8.1%)	3 (4.2%)	0.66	0.205	2.110	0.482
	20-39mg	10 (6.7%)	5 (6.9%)	1.23	0.489	3.079	0.662
	>40mg	10 (6.7%)	12 (16.7%)	2.30	1.225	4.322	0.010
Thiopurines		70 (47.0%)	36 (50.0%)	1.12	0.707	1.782	0.623
Methotrexate		11 (7.4%)	4 (5.6%)	0.77	0.279	2.098	0.604
Anti-TNF		34 (22.8%)	18(25.0%)	1.10	0.645	1.876	0.727
Medicatians Started Followina Hospitalization (within 3 months)
Thiopurines		33 (22.2%)	23 (31.9%)	1.53	0.934	2.515	0.091
Methotrexate		9(6.1%)	4 (5.6%)	0.83	0.303	2.278	0.719
Anti-TNF		24(16.1%)	16(22.2%)	1.49	0.734	3.017	0.269
Imaging Characteristics
Dilation ≥35mm		66 (±44.6)	52 (±72.2)	2.77	1.652	4.639	<.001
Diameter (mm)		33.9 (±12.78)	40.4 (±12.03)	1.03	1.007	1.044	0.006
Thickness (mm)		5.9 (±2.76)	7.2 (±2.47)	1.16	1.054	1.268	0.002
Disease Activity		98 (66.2%)	55 (76.4%)	1.49	0.864	2.565	0.152
Laboratory
WBC		10.56 (±4.96)	11.00 (±5.86)	1.02	0.974	1.064	0.420
HGB		13.02 (±1.84)	12.66 (±2.27)	0.93	0.822	1.046	0.217
PLT		309.2 (±116.1)	375.2 (±177.8)	1.01	1.000	1.016	<.001
Albumin		3.99 (±0.67)	3.85 (0.72)	0.82	0.597	1.121	0.211
PLT-Alb Ratio		81.0 (±39.7)	103.4 (±61.2)	1.01	1.003	1.012	<.001
PLT-Albumin Ratio (categorical)
	0-75	81 (54.4%)	31 (43.1%)		reference
	75-125	50 (33.6%)	21 (29.2%)	1.07	0.619	1.834	0.818
	>125	18 (12.1%)	20 (27.8%)	2.05	1.321	3.651	0.010

Rows highlighted in gray indicate statistical significance at or below the .05 level.